(Q38101836)

28 August 2017

Pseudomonas aeruginosa infection in cystic fibrosis lung disease and new perspectives of treatment: a review (English)

1 reference

28 August 2017

0 references

Pseudomonas aeruginosa

0 references

author name string

M C Gaspar

1

1 reference

28 August 2017

W Couet

2

1 reference

28 August 2017

J-C Olivier

3

1 reference

28 August 2017

A A C C Pais

4

1 reference

28 August 2017

J J S Sousa

5

1 reference

28 August 2017

26 April 2013

1 reference

European Journal of Clinical Microbiology & Infectious Diseases

28 August 2017

1 reference

28 August 2017

32

1 reference

28 August 2017

10

1 reference

28 August 2017

1231-1252

1 reference

https://scigraph.springernature.com/pub.10.1007/s10096-013-1876-y

28 August 2017

0 references

cites work

Recent advances in the treatment of Pseudomonas aeruginosa infections in cystic fibrosis

1 reference

https://api.crossref.org/works/10.1007%2FS10096-013-1876-Y

New concepts of the pathogenesis of cystic fibrosis lung disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10096-013-1876-Y

Antibiotic therapy against Pseudomonas aeruginosa in cystic fibrosis: a European consensus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10096-013-1876-Y

Challenges and advances in the development of inhalable drug formulations for cystic fibrosis lung disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10096-013-1876-Y

Management of pulmonary disease in patients with cystic fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10096-013-1876-Y

Novel concepts in evaluating antimicrobial therapy for bacterial lung infections in patients with cystic fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10096-013-1876-Y

Cystic fibrosis infections: treatment strategies and prospects.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10096-013-1876-Y

Airway surface dehydration in cystic fibrosis: pathogenesis and therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10096-013-1876-Y

Role of cilia, mucus, and airway surface liquid in mucociliary dysfunction: lessons from mouse models

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10096-013-1876-Y

Revisited physicochemical and transport properties of respiratory mucus in genotyped cystic fibrosis patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10096-013-1876-Y

Aerosol antibiotics: considerations in pharmacological and clinical evaluation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10096-013-1876-Y

Abnormal surface liquid pH regulation by cultured cystic fibrosis bronchial epithelium

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10096-013-1876-Y

Antibiotic treatment of CF lung disease: from bench to bedside

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10096-013-1876-Y

Review: Staphylococcus aureus and MRSA in cystic fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10096-013-1876-Y

New antimicrobial strategies in cystic fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10096-013-1876-Y

Microbial ecology of the cystic fibrosis lung

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10096-013-1876-Y

Challenging and emerging pathogens in cystic fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10096-013-1876-Y

Macrolide and clindamycin resistance in Streptococcus milleri group isolates from the airways of cystic fibrosis patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10096-013-1876-Y

Treatment of lung infection in patients with cystic fibrosis: current and future strategies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10096-013-1876-Y

The airway microbiota in cystic fibrosis: a complex fungal and bacterial community--implications for therapeutic management

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10096-013-1876-Y

Microbial diversity in the cystic fibrosis airways: where is thy sting?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10096-013-1876-Y

The airway microbiome in cystic fibrosis and implications for treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10096-013-1876-Y

The cystic fibrosis airway microbiome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10096-013-1876-Y

The treatment of respiratory pseudomonas infection in cystic fibrosis: what drug and which way?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10096-013-1876-Y

Pseudomonas acquisition in young patients with cystic fibrosis: pathophysiology, diagnosis, and management

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10096-013-1876-Y

Molecular epidemiology of chronic Pseudomonas aeruginosa airway infections in cystic fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10096-013-1876-Y

Molecular epidemiology of Pseudomonas aeruginosa, Burkholderia cepacia complex and methicillin-resistant Staphylococcus aureus in a cystic fibrosis center.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10096-013-1876-Y

Evaluation of a new definition for chronic Pseudomonas aeruginosa infection in cystic fibrosis patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10096-013-1876-Y

Application of quantitative PCR to the diagnosis and monitoring of Pseudomonas aeruginosa colonization in 5-18-year-old cystic fibrosis patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10096-013-1876-Y

PCR and the detection of Pseudomonas aeruginosa in respiratory samples of CF patients. A literature review

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10096-013-1876-Y

Systemic, nasal and oral live vaccines against Pseudomonas aeruginosa: a clinical trial of immunogenicity in lower airways of human volunteers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10096-013-1876-Y

A double-blind randomized placebo-controlled phase III study of a Pseudomonas aeruginosa flagella vaccine in cystic fibrosis patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10096-013-1876-Y

Antibiotic resistance of bacterial biofilms

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10096-013-1876-Y

Outer membrane permeability in Pseudomonas cepacia: diminished porin content in a beta-lactam-resistant mutant and in resistant cystic fibrosis isolates

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10096-013-1876-Y

Chloramphenicol resistance in Pseudomonas cepacia because of decreased permeability

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10096-013-1876-Y

Prevention of drug access to bacterial targets: permeability barriers and active efflux

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10096-013-1876-Y

Semimechanistic pharmacokinetic-pharmacodynamic model with adaptation development for time-kill experiments of ciprofloxacin against Pseudomonas aeruginosa

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10096-013-1876-Y

Resistance to tobramycin and colistin in isolates of Pseudomonas aeruginosa from chronically colonized patients with cystic fibrosis under antimicrobial treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10096-013-1876-Y

Microparticles for inhalational delivery of antipseudomonal antibiotics

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10096-013-1876-Y

Cystic fibrosis pulmonary guidelines: treatment of pulmonary exacerbations

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10096-013-1876-Y

Tissue concentrations: do we ever learn?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10096-013-1876-Y

Interpretation of antibiotic concentration ratios measured in epithelial lining fluid

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10096-013-1876-Y

Development of the first inhaled antibiotic for the treatment of cystic fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10096-013-1876-Y

Reduced mortality in cystic fibrosis patients treated with tobramycin inhalation solution

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10096-013-1876-Y

Optimization of anti-pseudomonal antibiotics for cystic fibrosis pulmonary exacerbations: III. fluoroquinolones

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10096-013-1876-Y

A survey of the utilization of anti-pseudomonal beta-lactam therapy in cystic fibrosis patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10096-013-1876-Y

Optimization of anti-pseudomonal antibiotics for cystic fibrosis pulmonary exacerbations: I. aztreonam and carbapenems

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10096-013-1876-Y

Optimization of anti-pseudomonal antibiotics for cystic fibrosis pulmonary exacerbations: II. cephalosporins and penicillins

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10096-013-1876-Y

Colistin pharmacokinetics: the fog is lifting

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10096-013-1876-Y

Polymyxin B and colistimethate are comparable as to efficacy and renal toxicity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10096-013-1876-Y

Effect of nebulized colistin sulphate and colistin sulphomethate on lung function in patients with cystic fibrosis: a pilot study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10096-013-1876-Y

Dry powder inhalation of antibiotics in cystic fibrosis therapy: part 2. Inhalation of a novel colistin dry powder formulation: a feasibility study in healthy volunteers and patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10096-013-1876-Y

Fosfomycin for Pseudomonas-related exacerbations of cystic fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10096-013-1876-Y

Fosfomycin therapy for multiresistant Pseudomonas aeruginosa in cystic fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10096-013-1876-Y

Pharmacokinetics of intravenous and oral linezolid in adults with cystic fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10096-013-1876-Y

Use of linezolid in pediatrics: a critical review

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10096-013-1876-Y

Pharmacological issues of linezolid: an updated critical review

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10096-013-1876-Y

Emerging therapies in cystic fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10096-013-1876-Y

Status of gene therapy for cystic fibrosis lung disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10096-013-1876-Y

Relationship between antimicrobial proteins and airway inflammation and infection in cystic fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10096-013-1876-Y

Antimicrobial peptides and proteins in the innate defense of the airway surface

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10096-013-1876-Y

Binding of protegrin-1 to Pseudomonas aeruginosa and Burkholderia cepacia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10096-013-1876-Y

Vaccines and immunotherapy against Pseudomonas aeruginosa

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10096-013-1876-Y

Economic effects of an eradication protocol for first appearance of Pseudomonas aeruginosa in cystic fibrosis patients: 1995 vs. 2009.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10096-013-1876-Y

Treatment of early Pseudomonas aeruginosa infection in patients with cystic fibrosis: the ELITE trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10096-013-1876-Y

Early anti-pseudomonal acquisition in young patients with cystic fibrosis: rationale and design of the EPIC clinical trial and observational study'

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10096-013-1876-Y

Cystic fibrosis pulmonary guidelines: chronic medications for maintenance of lung health.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10096-013-1876-Y

Respirable microspheres for inhalation: the potential of manipulating pulmonary disposition for improved therapeutic efficacy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10096-013-1876-Y

Aerosol therapy with colistin methanesulfonate: a biopharmaceutical issue illustrated in rats.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10096-013-1876-Y

Formulation strategy and use of excipients in pulmonary drug delivery

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10096-013-1876-Y

Pseudomonas aeruginosa biofilms in the respiratory tract of cystic fibrosis patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10096-013-1876-Y

The future of inhaled antibiotic therapy. New products

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10096-013-1876-Y

Influence of particle size on regional lung deposition--what evidence is there?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10096-013-1876-Y

Deposition of inhaled particles in the human respiratory tract and consequences for regional targeting in respiratory drug delivery

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10096-013-1876-Y

Characterization of inhalation aerosols: a critical evaluation of cascade impactor analysis and laser diffraction technique.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10096-013-1876-Y

Particle size design of PLGA microspheres for potential pulmonary drug delivery using response surface methodology

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10096-013-1876-Y

Engineering biodegradable polyester particles with specific drug targeting and drug release properties

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10096-013-1876-Y

Surfactant-free, biodegradable nanoparticles for aerosol therapy based on the branched polyesters, DEAPA-PVAL-g-PLGA.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10096-013-1876-Y

Mathematical modeling of molecular diffusion through mucus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10096-013-1876-Y

Barrier properties of mucus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10096-013-1876-Y

Enhanced Pseudomonas aeruginosa biofilm development mediated by human neutrophils

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10096-013-1876-Y

The penetration of fresh undiluted sputum expectorated by cystic fibrosis patients by non-adhesive polymer nanoparticles.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10096-013-1876-Y

Rapid transport of large polymeric nanoparticles in fresh undiluted human mucus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10096-013-1876-Y

Cystic fibrosis sputum: a barrier to the transport of nanospheres

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10096-013-1876-Y

On the transport of lipoplexes through cystic fibrosis sputum

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10096-013-1876-Y

Nacystelyn enhances adenoviral vector-mediated gene delivery to mouse airways

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10096-013-1876-Y

Mucus altering agents as adjuncts for nonviral gene transfer to airway epithelium

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10096-013-1876-Y

Inhalable antibiotic delivery using a dry powder co-delivering recombinant deoxyribonuclease and ciprofloxacin for treatment of cystic fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10096-013-1876-Y

Mannitol-guided delivery of Ciprofloxacin in artificial cystic fibrosis mucus model

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10096-013-1876-Y

Co-spray-dried mannitol-ciprofloxacin dry powder inhaler formulation for cystic fibrosis and chronic obstructive pulmonary disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10096-013-1876-Y

Pharmacokinetics and safety of MP-376 (levofloxacin inhalation solution) in cystic fibrosis subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10096-013-1876-Y

Aztreonam inhalation solution for suppressive treatment of chronic Pseudomonas aeruginosa lung infection in cystic fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10096-013-1876-Y

Aztreonam (for inhalation solution) for the treatment of chronic lung infections in patients with cystic fibrosis: an evidence-based review

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10096-013-1876-Y

Aztreonam lysine for inhalation solution: in cystic fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10096-013-1876-Y

Pulmonary formulations: what remains to be done?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10096-013-1876-Y

Controlled release antibiotics for dry powder lung delivery

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10096-013-1876-Y

Dry powder inhalation of colistin in cystic fibrosis patients: a single dose pilot study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10096-013-1876-Y

A randomised clinical trial of nebulised tobramycin or colistin in cystic fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10096-013-1876-Y

Safety, efficacy and convenience of colistimethate sodium dry powder for inhalation (Colobreathe DPI) in patients with cystic fibrosis: a randomised study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10096-013-1876-Y

Novel sustained release microspheres for pulmonary drug delivery

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10096-013-1876-Y

Antibacterial activity of liposomal gentamicin against Pseudomonas aeruginosa: a time-kill study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10096-013-1876-Y

Liposome-mediated gentamicin delivery: development and activity against resistant strains of Pseudomonas aeruginosa isolated from cystic fibrosis patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10096-013-1876-Y

Microspheres for controlled release drug delivery

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10096-013-1876-Y

Preparation of uniform-sized multiple emulsions and micro/nano particulates for drug delivery by membrane emulsification

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10096-013-1876-Y

PLGA, chitosan or chitosan-coated PLGA microparticles for alveolar delivery? A comparative study of particle stability during nebulization.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10096-013-1876-Y

Development of highly porous large PLGA microparticles for pulmonary drug delivery

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10096-013-1876-Y

Preparation of large porous biodegradable microspheres by using a simple double-emulsion method for capreomycin sulfate pulmonary delivery

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10096-013-1876-Y

Feasibility study of aerosolized prostaglandin E1 microspheres as a noninvasive therapy for pulmonary arterial hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10096-013-1876-Y

Chitosan microspheres for intrapulmonary administration of moxifloxacin: interaction with biomembrane models and in vitro permeation studies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10096-013-1876-Y

Mucoadhesive microspheres for controlled drug delivery

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10096-013-1876-Y

Mechanisms of resistance to beta-lactam antibiotics amongst Pseudomonas aeruginosa isolates collected in the UK in 1993.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10096-013-1876-Y

Inhalable microparticles containing drug combinations to target alveolar macrophages for treatment of pulmonary tuberculosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10096-013-1876-Y

Gemcitabine-loaded chitosan microspheres. Characterization and biological in vitro evaluation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10096-013-1876-Y

Preparation and release of salbutamol from chitosan and chitosan co-spray dried compacts and multiparticulates

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10096-013-1876-Y

Mucoadhesive beclomethasone microspheres for powder inhalation: their pharmacokinetics and pharmacodynamics evaluation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10096-013-1876-Y

Ofloxacin targeting to lungs by way of microspheres.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10096-013-1876-Y

Factorial design, physicochemical characterisation and activity of ciprofloxacin-PLGA nanoparticles

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10096-013-1876-Y

Therapeutic approaches to chronic cystic fibrosis respiratory infections with available, emerging aerosolized antibiotics

21 January 2018

1 reference

12 December 2020

Pseudomonas aeruginosa outer membrane permeability: isolation of a porin protein F-deficient mutant

1 reference

12 December 2020

Respirable PLGA microspheres containing rifampicin for the treatment of tuberculosis: manufacture and characterization

1 reference

12 December 2020

Challenges in inhaled product development and opportunities for open innovation

1 reference

12 December 2020

Formulation and in vitro characterization of inhalable rifampicin-loaded PLGA microspheres for sustained lung delivery

1 reference

12 December 2020

Aerosol antibiotics in cystic fibrosis.

1 reference

12 December 2020

Prevalence of efflux-mediated ciprofloxacin and levofloxacin resistance in recent clinical isolates of Pseudomonas aeruginosa and its reversal by the efflux pump inhibitors 1-(1-naphthylmethyl)-piperazine and phenylalanine-arginine-β-naphthylamide

1 reference

12 December 2020

Mechanism of adaptive resistance to aminoglycosides of Pseudomonas aeruginosa

1 reference

12 December 2020

The newer fluoroquinolones

1 reference

12 December 2020

[Early antibiotic treatment for eradication of initial infection by Pseudomonas aeruginosa in patients with cystic fibrosis]

1 reference

12 December 2020

[Inhaled antibiotic therapy in cystic fibrosis]

1 reference

12 December 2020

In vitro activity of minocycline against respiratory pathogens from patients with cystic fibrosis

1 reference

12 December 2020

A problem in the interpretation of beta-lactam antibiotic levels in tissues

1 reference

12 December 2020

The role of mucus viscoelasticity in cough clearance.

1 reference

12 December 2020

Emerging therapies for cystic fibrosis lung disease

1 reference

12 December 2020

Aztreonam lysine for inhalation solution in cystic fibrosis: profile report

1 reference

12 December 2020

Persistency of Pseudomonas aeruginosa in sputum cultures and clinical outcomes in adult patients with cystic fibrosis

1 reference

12 December 2020

Single-dose intrapulmonary pharmacokinetics of azithromycin, clarithromycin, ciprofloxacin, and cefuroxime in volunteer subjects.

1 reference

12 December 2020

Bugs, biofilms, and resistance in cystic fibrosis.

1 reference

12 December 2020

Multidrug-resistant pulmonary infection in cystic fibrosis--what does 'resistant' mean?

1 reference

12 December 2020

Influence of surface charge on the potential toxicity of PLGA nanoparticles towards Calu-3 cells.

1 reference

12 December 2020

Polycaprolactone Microspheres as Carriers for Dry Powder Inhalers: Effect of Surface Coating on Aerosolization of Salbutamol Sulfate

1 reference

12 December 2020

10.1007/S10096-013-1876-Y

Identifiers

DOI

1 reference

Dimensions Publication ID

28 August 2017

0 references

1 reference